Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at email@example.com
Saluda’s Spinal Cord Stimulation System Continues to Show Efficacy in New 36-Month Data
Similar to results at 24-months, findings showed improvements in patient outcomes with the SCS System including quality of life, functional ability, mood, and sleep.
Growing Brivaracetam’s Potential Through the Adaptive, Dose-Finding EXPAND Study
The trial’s 2-stage design seeks to answer questions about the dosing and efficacy of brivaracetam, a previously approved agent for partial-onset seizures in patients with childhood absence epilepsy and juvenile absence epilepsy.
Endovascular Brain-Computer Interface Implant Shows Feasibility, Safety in Treating Upper-Limb Paralysis
After a 12-month period, patients were able to use the implant for routine digital activities, such as texting, emailing, personal finance, online shopping, and communication of care needs.
Real-World Data of Spinal Muscular Atrophy Shows High Adherence to Nusinersen Dosing Regimen
Nearly 94% of nusinersen doses recorded in electronic health records database and more than 80% of doses recorded in the claims databases were received on time according to the recommended dosing schedule.
FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data
In the letter, the FDA specifically required that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continuous treatment with donanemab.
Ticagrelor and Aspirin Combination Most Effective in CYP2C19 Carriers With Low Risk Profile
The study provided class II evidence that CYP2C19 loss of function carriers with minor stroke or transient ischemic attack at low risk, but not high risk, of recurrent stroke received greater benefit from ticagrelor and aspirin rather than clopidogrel and aspirin.
Women Experience Greater Effects, Associated Symptoms of Cluster Headache
Between sexes, females with cluster headache reported longer bouts than male participants and used prophylactic treatment more often, as well as higher rates of diurnal rhythmicity.
NeuroVoices: Rachel Alvarez on Cure CMD’s Goal to Bring Patients and Clinicians Together
The executive director of Cure CMD provided perspective on a new 10-month program that aims to align patient and clinician perspectives on certain rare neuromuscular disorders.
Research Highlights Trends and Impacts of Comorbidities in NMOSD
Featuring a cohort of more than 500 patients with NMOSD, data showed that those with comorbidities exhibit multiple presentations and are more likely to relapse after immunotherapy.
Presence of PIRA Following First Demyelinating Event Worsens Long-Term Outcomes in MS
PIRA was associated with, for most patients, a sustained accumulation of disability, which was strongly associated with unfavorable long-term outcomes.
CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine
Despite previous data suggesting no link, the CDC and FDA will continue to review all evidence for possible increased risk of ischemic stroke.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
High-Dose Ulotaront Reduces REM Sleep Without Atonia in Healthy Individuals
Patients who had higher baseline REM without atonia levels were associated with the largest treatment effects on RSWA with a single 50 mg dose of ulotaront.
Understanding ALZ-801’s Impact on Alzheimer Pathologies, Brain Atrophy
Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.
Systematic Study Identifies Association Between Incident Parkinson Disease and Antiepileptic Drug Use
Not previously explored, new findings showed links between antiseizure drug prescriptions and incident PD, with trends towards increased risk in those with greater number of prescription issues and multiple AEDs.
Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations
In preclinical animal models, NRL-1049 showed an ability to decrease ROCK-2 activation, a pathway that is hyperactivated in patients with cerebral cavernous malformations.
Supportive Self-Management Program Shows No Efficacy in Improving QOL for Chronic Migraine
The trial found no evidence of any clinically relevant benefit from the CHESS intervention across multiple outcomes at multiple time points, nor in any sensitivity or subgroup analyses.
FDA Accepts sBLA for Revance’s Cervical Dystonia Treatment DaxibotulinumtoxinA
DaxibotulinumtoxinA, the first and only peptide formulated neuromodulator, has been shown to be safe and well tolerated in doses of 125 and 250 units, with clinically meaningful effect observed by both patients and clinicians.
Understanding the Widespread Impacts of The Ohio State University Wexner Medical Center’s Teleneurology Program
The virtual care program built by The Ohio State University Wexner Medical Center allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.
NeuroVoices: RJ Tesi, MD, on XPro1595 and the Role of TNF Inhibitors in the Alzheimer Field
The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.
NeuroDerm’s 24-Hour Subcutaneous Levodopa Infusion Meets Primary End Point in Phase 3 BouNDless Study
In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial.
Eisai Files Supplemental BLA for Traditional Approval of Lecanemab
Approved under the accelerated approval pathway, the current indication for lecanemab states the company must provide phase 4 study evidence to confirm the agent’s effect in Alzheimer disease.
ARISE Results Highlight Dimethyl Fumarate’s Impact as Disease-Modifying Therapy for RIS
For the first time ever, investigators identified a treatment benefit that extends the time to clinical conversion in RIS and reduces new or newly-enlarging T-weighted hyperintense lesions.
FDA Approves Eisai’s Lecanemab for the Treatment for Alzheimer Disease
Marketed as Leqembi, the agent was approved through the accelerated approval pathway and was based on a major study featuring almost 900 patients with early Alzheimer disease.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Clinicians Raise Concerns Over Lecanemab Following Patient Death Treated With tPA for Stroke
In the phase 3 Clarity AD trial, a 65-year-old patient treated with lecanemab died because of multiple cerebral hemorrhages after undergoing tissue plasminogen activator therapy for ischemic stroke.
Timing of Orthostatic Hypotension, Not Symptom Severity, Increases Dementia Risk in Parkinson Disease, Multiple System Atrophy
The increased risk of dementia in patients showing early orthostatic hypotension was independent of the presence of concomitant supine hypertension and other factors associated with cognitive impairment.
FDA Clears First Stroke-Specific Radial Access Platform for Mechanical Thrombectomy
With this new approval, the Zoom RDL becomes the newest addition to Imperative’s Zoom Stroke Solution, a complete stroke system designed for effective clot removal in ischemic stroke.
Links Identified Between Depression and Postural Instability in Early-Stage Parkinson Disease
Data from a cohort of nearly 100 patients with Parkinson disease suggest there are shared nondopaminergic pathogenic mechanisms between depression and postural instability symptoms of the disease.
NeuroVoices: Joe Verghese, MBBS, MS, on the 5-Cog Assessment as an Alzheimer Screening Tool in Primary Care Settings
The director of the Montefiore Einstein Center for the Aging Brain provided perspective on a new study assessing the use of a novel tool aimed to confirm patients’ cognitive complaints and issues with mobility.
2 Clarke Drive Cranbury, NJ 08512